The behavioral pharmacology of hallucinogens - Test2 - elhamkhani - TriplyDB

The behavioral pharmacology of hallucinogens

The behavioral pharmacology of hallucinogens

http://www.wikidata.org/entity/Q24645656

about

Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.The HIV antiretroviral drug efavirenz has LSD-like properties Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions Lysergic acid diethylamide: a drug of 'use'?Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature Recreational use, analysis and toxicity of tryptamines Effects of MDMA Injections on the Behavior of Socially-Housed Long-Tailed Macaques (Macaca fascicularis)NPS: Medical Consequences Associated with Their Intake Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?Psychedelics Modern Clinical Research on LSD.Animal models of serotonergic psychedelics.Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.Intracranial self-stimulation to evaluate abuse potential of drugs.Abuse liability profile of three substituted tryptamines.Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice.Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice.The hallucinogenic world of tryptamines: an updated review.Clinical applications of hallucinogens: A review.Novel psychoactive substances of interest for psychiatry.Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice.Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice Monoamine transporters: vulnerable and vital doorkeepers.High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.Effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and quipazine on heroin self-administration in rhesus monkeys.Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys: antagonism and apparent pA2 analyses Communication networks in the brain: neurons, receptors, neurotransmitters, and alcohol.Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice.Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function.Marine indole alkaloids: potential new drug leads for the control of depression and anxiety.Serotonergic agents in the management of cluster headache.Functional selectivity in GPCR heterocomplexes.Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses.Alternative drugs of abuse.Anxiolytic drug discovery: what are the novel approaches and how can we improve them?Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.

P2860

Q21134103-51605FD5-9876-4460-A19F-BF64E0F284A3 Q24595389-74719134-7D16-4CE9-9EA9-3F6EB7BC206A Q24608183-487EAA8A-75BD-461A-9CC8-DAD20CA2D662 Q24633393-5342CA35-69D1-4BDE-91AC-9FF4DBE23435 Q26746133-180086F0-3D82-4EAA-8F99-A621F4FE5972 Q26752739-207A8122-91C4-4169-BD77-5517FA55688F Q26865329-92A637A9-9777-4268-A958-2572F851DEA2 Q27027080-EA98C607-E0A7-4EEA-AF31-2A07FB00E8F4 Q27329826-387E8EFB-A84B-43D0-B90A-DAB714BD152C Q28276182-D8A2E243-4389-42D0-BF72-C887F75D9BD2 Q28540537-B47E3BC7-CDF7-4493-AC3A-02F9B9DA0802 Q30359998-6726E58C-A7F1-4443-9B5B-23B731FC39BB Q30401421-3CFF819F-D384-4DF5-A655-539948378403 Q30444312-4837F888-0130-41DF-96BF-F60F2FD355E9 Q30457813-15966B9A-0094-41E5-B7E2-DE4755C826E0 Q33845750-E269600D-0A4C-4878-8E68-C00D8B0B0A00 Q34176654-67C383F6-94AB-41B3-96C2-1A67FDA5970B Q34359895-C544A563-75D8-4338-A8CF-0B68AE64787F Q34438870-646119F5-56C5-4DF9-BB3E-2D972426E347 Q34471834-E03BA62D-1352-4131-BA72-7A9B0D34C674 Q34535259-02AB6D5C-FF32-45AC-A4E2-48F8506C74ED Q34667835-8AFE3F74-EDB3-497B-B8C6-E8991D26724B Q35024752-C3E6EAB1-EBEA-48E2-8ED7-DA425C551659 Q35085860-434308CA-35DB-441E-B5BD-EE30A8AE1298 Q35877150-64E16310-0632-41C6-994E-CD5603D89E7A Q36839080-9927FE67-B296-4910-B255-83B57A14AFE1 Q36969769-0240E0AB-AB6B-4A1A-B744-D2AB34A47A42 Q37050150-7674B281-18A8-4D6C-97D1-F93F826107FB Q37113859-0526AF0F-F10F-450D-A6F1-4891EFA8F06D Q37192714-C72BCF46-F098-49AF-AC9A-CABA280BCA23 Q37386620-6BE02DF6-5BBF-4BA3-BEB1-6835DBD501F0 Q37416406-DFD4EAD7-7D15-4968-99AB-929EA85F2572 Q37622283-247E65CE-C909-49AC-BBED-D1D7128EDD84 Q37727948-8EBE6493-28BE-4253-BAB0-FE37672D52E2 Q37832687-BF887383-C3D2-4B16-BE0E-7723BD1AA80D Q38017279-B0ADFC53-F94E-4A50-AD37-4279C644DF4E Q38023813-EB96F0D2-03D6-4929-A0F9-42F08223C98C Q38103475-E3B6461B-9B27-4077-86A3-B6E0385E9F78 Q38160918-B0F844D0-AE13-49F2-95C0-B0EB30B9BEA5 Q39052265-990F81CF-1EBF-47F5-8805-178E73210D3D

P2860

The behavioral pharmacology of hallucinogens

http://www.wikidata.org/entity/Q24645656

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

The behavioral pharmacology of hallucinogens

@ast

The behavioral pharmacology of hallucinogens

@en

The behavioral pharmacology of hallucinogens

@nl

type

label

The behavioral pharmacology of hallucinogens

@ast

The behavioral pharmacology of hallucinogens

@en

The behavioral pharmacology of hallucinogens

@nl

prefLabel

The behavioral pharmacology of hallucinogens

@ast

The behavioral pharmacology of hallucinogens

@en

The behavioral pharmacology of hallucinogens

@nl

P1433

Q24645656-4F2FE69C-3ABC-4B94-A30C-DC66E9D7BD60

P1476

Q24645656-E80152E4-2AAE-4F1E-A558-2B3728B8C577

P2093

Q24645656-2AD0AEA1-BE06-4B6E-8F7A-E7F47756837D

Q24645656-37993EE3-A441-4A63-8A90-6591F0D2562D

Q24645656-82AB04AA-4CCB-4456-89E6-636BDA769A2C

P2860

Q24645656-00E4BFE3-A741-4BF9-B862-15DD77464958

Q24645656-08332AA0-6607-4D37-964C-DEA2C48EF630

Q24645656-08C5314D-727B-48CA-B919-46ED6D52853C

Q24645656-0C204960-10C2-4ED6-BAE7-BD30806480F4

Q24645656-0CBDFD13-1C47-4137-8D22-725C63CFA229

Q24645656-0F2B4C33-37C4-4B09-8415-85BF68BF4AA9

Q24645656-0F50A596-C1AF-49AA-8CA5-EC37CD7C40BF

Q24645656-14C8F45B-1DFD-4614-B1D3-353797BBF8FC

Q24645656-17D4A089-11B8-4AF4-AB88-AE0633E3C294

Q24645656-1A53F8FB-EE72-4483-8800-B9E13C770C99

P304

Q24645656-DBB1B0A9-AFEC-4F08-AE99-03D3B89CCE8B

P31

Q24645656-C4EB3D83-F677-4C9A-9CD3-D9C34CCF48A7

P3181

Q24645656-1136470C-6121-469A-8691-2FDE79F85CA7

P356

Q24645656-A756AC03-FCB3-4E95-B44B-DBC04965A99E

P407

Q24645656-574765B9-8692-46E6-87D6-967FAA8EDC32

P433

Q24645656-EE0E0381-8B79-44E4-9E77-DB9108190E8E

P478

Q24645656-B7198015-9B1B-4672-9134-675DE3CDD6C5

P577

Q24645656-4F064FCA-1CBB-47E3-872D-58917918CBF0

P5875

Q24645656-DDC5A069-811D-42FE-BE13-8736F53DEDBA

P698

Q24645656-6D352EC6-24CB-45AA-9B0A-CC5892045647

P921

Q24645656-2C4BE690-0AF0-4E45-97A3-3156CE235747

P932

Q24645656-175F6FA2-9540-477A-B0ED-A4F459133431

P3181

P356

J.BCP.2007.07.018

P1433

Biochemical Pharmacology

P1476

The behavioral pharmacology of hallucinogens

@en

P2093

Chad J Reissig

http://www.w3.org/2001/XMLSchema#string

Kevin S Murnane

http://www.w3.org/2001/XMLSchema#string

William E Fantegrossi

http://www.w3.org/2001/XMLSchema#string

P2860

Functional Selectivity and Classical Concepts of Quantitative Pharmacology

Lysergamides of Isomeric 2,4-Dimethylazetidines Map the Binding Orientation of the Diethylamide Moiety in the Potent Hallucinogenic Agent N , N -Diethyllysergamide (LSD)

Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor

Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells

Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex

Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors

A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes

Multiplicity of mechanisms of serotonin receptor signal transduction

P304

17-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2217004

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.BCP.2007.07.018

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5868092

http://www.w3.org/2001/XMLSchema#string

P698

17977517

http://www.w3.org/2001/XMLSchema#string

P921

P932

2247373

http://www.w3.org/2001/XMLSchema#string